Home / Health / mRNA Flu Shot: A New Era in Vaccine Tech?
mRNA Flu Shot: A New Era in Vaccine Tech?
18 Jun
Summary
- Moderna's mRNA flu vaccine is being reviewed by FDA advisers.
- The vaccine uses mRNA technology, similar to COVID-19 vaccines.
- Study showed a 27% reduction in flu cases compared to another vaccine.
U.S. health advisors are currently debating the approval of Moderna's mFlusiva, a novel flu vaccine utilizing mRNA technology. This approach, familiar from COVID-19 vaccines, could offer a faster way to produce updated doses if the influenza virus significantly mutates. The vaccine is being considered for individuals aged 50 and older, with a recent study showing a 27% decrease in flu cases compared to a routinely used vaccine.
The FDA has published a favorable review of Moderna's data, reporting no safety issues. The agency is seeking full approval for those aged 50-64 and authorization for older adults pending further testing. An earlier dispute involved an FDA official's concern about the comparison vaccine used in studies, but the application was eventually accepted.
While the new vaccine demonstrated efficacy and similar antibody generation to a high-dose senior shot in smaller studies, the FDA noted a lack of data for very frail older adults and those with compromised immune systems. The review and discussion are critical steps before the upcoming winter flu season.
